Esophageal cancer - French intergroup clinical practice guidelines for diagnosis, treatments and follow-up (TNCD, SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, ACHBT, SFP, RENAPE, SNFCP, AFEF, SFR).

[1]  F. Lordick,et al.  Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. , 2022, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  E. Van Cutsem,et al.  MATTERHORN: phase III study of durvalumab plus FLOT chemotherapy in resectable gastric/gastroesophageal junction cancer. , 2022, Future oncology.

[3]  M. Vieth,et al.  Endoscopic submucosal dissection for superficial gastrointestinal lesions: European Society of Gastrointestinal Endoscopy (ESGE) Guideline - Update 2022. , 2022, Endoscopy.

[4]  E. Schoon,et al.  Analysis of metastases rates during follow-up after endoscopic resection of early "high-risk" esophageal adenocarcinoma. , 2022, Gastrointestinal endoscopy.

[5]  J. Ajani,et al.  Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma. , 2022, The New England journal of medicine.

[6]  A. Mcgregor,et al.  Physiotherapy Regimens in Esophagectomy and Gastrectomy: a Systematic Review and Meta-Analysis , 2021, Annals of Surgical Oncology.

[7]  X. Lenne,et al.  Effect of Phased Implementation of Totally Minimally Invasive Ivor Lewis Esophagectomy for Esophageal Cancer after Previous Adoption of the Hybrid Minimally Invasive Technique: Results from a French Nationwide Population-Based Cohort Study , 2021, Annals of Surgical Oncology.

[8]  A. Bertaut,et al.  Exclusive Chemoradiotherapy With or Without Radiation Dose Escalation in Esophageal Cancer: Multicenter Phase 2/3 Randomized Trial CONCORDE (PRODIGE-26). , 2021, International journal of radiation oncology, biology, physics.

[9]  T. Fujita,et al.  Long-term clinical outcome after endoscopic resection of esophageal squamous cell carcinoma invading the muscularis mucosae without lymphovascular invasion. , 2021, Gastrointestinal endoscopy.

[10]  R. van Hillegersberg,et al.  Robot-assisted minimally invasive thoraco-laparoscopic esophagectomy versus minimally invasive esophagectomy for resectable esophageal adenocarcinoma, a randomized controlled trial (ROBOT-2 trial) , 2021, BMC Cancer.

[11]  V. Gebski,et al.  Individual patient data meta-analysis of neoadjuvant chemotherapy followed by surgery versus upfront surgery for carcinoma of the oesophagus or the gastro-oesophageal junction. , 2021, European journal of cancer.

[12]  M. Vieth,et al.  Endoscopic tissue sampling – Part 1: Upper gastrointestinal and hepatopancreatobiliary tracts. European Society of Gastrointestinal Endoscopy (ESGE) Guideline , 2021, Endoscopy.

[13]  Sung-Bae Kim,et al.  Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study , 2021, The Lancet.

[14]  S. Tsunoda,et al.  Parallel-group controlled trial of surgery versus chemoradiotherapy in patients with stage I esophageal squamous cell carcinoma. , 2021, Gastroenterology.

[15]  Q. Xue,et al.  Postoperative Adjuvant therapy versus Surgery Alone for Stage IIB-III Esophageal Squamous Cell Carcinoma: A Phase III Randomized Controlled Trial. , 2021, The oncologist.

[16]  E. D. Geijsen,et al.  Randomized Study on Dose Escalation in Definitive Chemoradiation for Patients With Locally Advanced Esophageal Cancer (ARTDECO Study) , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  G. Piessen,et al.  Uselessness and danger of dilating obstructive esophageal for staging purpose: a confirmation. , 2021, The Annals of thoracic surgery.

[18]  Hester F. Lingsma,et al.  Updated protocol of the SANO trial: a stepped-wedge cluster randomised trial comparing surgery with active surveillance after neoadjuvant chemoradiotherapy for oesophageal cancer , 2021, Trials.

[19]  F. Daams,et al.  Intrathoracic vs Cervical Anastomosis After Totally or Hybrid Minimally Invasive Esophagectomy for Esophageal Cancer: A Randomized Clinical Trial. , 2021, JAMA surgery.

[20]  Sung-Bae Kim,et al.  Chemoradiotherapy Followed by Active Surveillance Versus Standard Esophagectomy for Esophageal Cancer , 2021, Annals of surgery.

[21]  E. Steyerberg,et al.  Ten-Year Outcome of Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal Cancer: The Randomized Controlled CROSS Trial , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  J. Ajani,et al.  Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer. , 2021, The New England journal of medicine.

[23]  S. Sami,et al.  Accuracy of clinical staging for T2N0 oesophageal cancer: systematic review and meta-analysis. , 2021, Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus.

[24]  C. Hurt,et al.  Palliative radiotherapy after oesophageal cancer stenting (ROCS): a multicentre, open-label, phase 3 randomised controlled trial , 2021, The lancet. Gastroenterology & hepatology.

[25]  S. Msika,et al.  Five-Year Survival Outcomes of Hybrid Minimally Invasive Esophagectomy in Esophageal Cancer: Results of the MIRO Randomized Clinical Trial. , 2021, JAMA surgery.

[26]  N. Uedo,et al.  Narrow band imaging under less-air condition improves the visibility of superficial esophageal squamous cell carcinoma , 2020, BMC Gastroenterology.

[27]  Sung-Bae Kim,et al.  Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  Y. Bang,et al.  Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial. , 2020, JAMA oncology.

[29]  W. Bechstein,et al.  1421MO Final results and subgroup analysis of the PETRARCA randomized phase II AIO trial: Perioperative trastuzumab and pertuzumab in combination with FLOT versus FLOT alone for HER2 positive resectable esophagogastric adenocarcinoma , 2020 .

[30]  B. Wallner,et al.  Surgical Morbidity and Mortality From the Multicenter Randomized Controlled NeoRes II Trial: Standard Versus Prolonged Time to Surgery After Neoadjuvant Chemoradiotherapy for Esophageal Cancer. , 2020, Annals of surgery.

[31]  Long-Qi Chen,et al.  A meta-analysis on surgery with or without postoperative radiotherapy to treat squamous cell esophageal carcinoma. , 2020, International journal of surgery.

[32]  T. Yano,et al.  Long-term outcome of endoscopic resection for intramucosal esophageal squamous cell cancer: a secondary analysis of the Japan Esophageal Cohort study , 2020, Endoscopy.

[33]  C. Haie-meder,et al.  Esophageal brachytherapy: Institut Gustave Roussy's experience. , 2020, Brachytherapy.

[34]  M. Cuesta,et al.  Implementation of Minimally Invasive Esophagectomy From a Randomized Controlled Trial Setting to National Practice. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  Y. Ba,et al.  Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study. , 2020, The Lancet. Oncology.

[36]  M. Rovers,et al.  Totally minimally invasive esophagectomy versus hybrid minimally invasive esophagectomy: systematic review and meta-analysis , 2020, Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus.

[37]  J. Newell,et al.  Preoperative exercise to improve fitness in patients undergoing complex surgery for cancer of the lung or oesophagus (PRE-HIIT): protocol for a randomized controlled trial , 2020, BMC Cancer.

[38]  K. Lam,et al.  Accuracy of detecting residual disease after neoadjuvant chemoradiotherapy for esophageal squamous cell carcinoma (preSINO trial): a prospective multicenter diagnostic cohort study , 2020, BMC Cancer.

[39]  G. Piessen,et al.  What are the Particularities of Oesophageal Surgery in Cirrhotic Patients. , 2020, Chirurgia.

[40]  K. Shao,et al.  Postoperative Radiotherapy in Pathological T2-3N0M0 Thoracic Esophageal Squamous Cell Carcinoma: Interim Report of a Prospective, Phase III, Randomized Controlled Study. , 2020, The oncologist.

[41]  J. Tuech,et al.  Thoracoscopy in prone position with two-lung ventilation compared to conventional thoracotomy during Ivor Lewis procedure: a multicenter case–control study , 2020, Surgical Endoscopy.

[42]  A. Lièvre,et al.  Nal-IRI/LV5-FU versus paclitaxel as second-line therapy in patients with metastatic esophageal squamous cell carcinoma (OESIRI)-PRODIGE 62: A multicentre, randomised, non-comparative phase II study. , 2019, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[43]  N. Ndegwa,et al.  Association between time interval from neoadjuvant chemoradiotherapy to surgery and complete histological tumor response in esophageal and gastroesophageal junction cancer: a national cohort study , 2019, Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus.

[44]  W. Schreurs,et al.  Accuracy of 18F-FDG PET/CT in Predicting Residual Disease After Neoadjuvant Chemoradiotherapy for Esophageal Cancer , 2019, The Journal of Nuclear Medicine.

[45]  Sung-Bae Kim,et al.  Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial. , 2019, The Lancet. Oncology.

[46]  G. Darling,et al.  Neoadjuvant therapy versus upfront surgery for clinical T2N0 esophageal cancer: A systematic review. , 2019, The Annals of thoracic surgery.

[47]  T. Yano,et al.  Efficacy of Endoscopic Resection and Selective Chemoradiotherapy for Stage I Esophageal Squamous Cell Carcinoma. , 2019, Gastroenterology.

[48]  R. Hua,et al.  Robot-assisted esophagectomy (RAE) versus conventional minimally invasive esophagectomy (MIE) for resectable esophageal squamous cell carcinoma: protocol for a multicenter prospective randomized controlled trial (RAMIE trial, robot-assisted minimally invasive Esophagectomy) , 2019, BMC Cancer.

[49]  I. B. Borel Rinkes,et al.  Robot-assisted Minimally Invasive Thoracolaparoscopic Esophagectomy Versus Open Transthoracic Esophagectomy for Resectable Esophageal Cancer: A Randomized Controlled Trial , 2019, Annals of surgery.

[50]  S. Markar,et al.  The evolution of fast track protocols after oesophagectomy. , 2019, Journal of thoracic disease.

[51]  E. Schoon,et al.  Endoscopic resection for early esophageal carcinoma. , 2019, Journal of thoracic disease.

[52]  S. Msika,et al.  Hybrid Minimally Invasive Esophagectomy for Esophageal Cancer , 2019, The New England journal of medicine.

[53]  F. Carli,et al.  Effect of Exercise and Nutrition Prehabilitation on Functional Capacity in Esophagogastric Cancer Surgery: A Randomized Clinical Trial , 2018, JAMA surgery.

[54]  T. Rockall,et al.  A randomised controlled trial to assess whether prehabilitation improves fitness in patients undergoing neoadjuvant treatment prior to oesophagogastric cancer surgery: study protocol , 2018, BMJ Open.

[55]  Xinchen Sun,et al.  Does timing of esophagectomy following neoadjuvant chemoradiation affect outcomes? A meta-analysis. , 2018, International journal of surgery.

[56]  O. Ljungqvist,et al.  Guidelines for Perioperative Care in Esophagectomy: Enhanced Recovery After Surgery (ERAS®) Society Recommendations , 2018, World Journal of Surgery.

[57]  S. Friesland,et al.  Neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the esophagus or gastroesophageal junction: long-term results of a randomized clinical trial. , 2018, Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus.

[58]  E. Van Cutsem,et al.  Phase III, randomised trial of avelumab versus physician’s choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300 , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[59]  E. Steyerberg,et al.  Detection of residual disease after neoadjuvant chemoradiotherapy for oesophageal cancer (preSANO): a prospective multicentre, diagnostic cohort study. , 2018, The Lancet. Oncology.

[60]  Kazuhiro Yoshida,et al.  Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial , 2018, The Lancet.

[61]  X. D'Journo.  Clinical implication of the innovations of the 8th edition of the TNM classification for esophageal and esophago-gastric cancer. , 2018, Journal of thoracic disease.

[62]  F. Backx,et al.  Multicentre randomized clinical trial of inspiratory muscle training versus usual care before surgery for oesophageal cancer , 2018, The British journal of surgery.

[63]  E. Steyerberg,et al.  Neoadjuvant chemoradiotherapy plus surgery versus active surveillance for oesophageal cancer: a stepped-wedge cluster randomised trial , 2018, BMC Cancer.

[64]  J. Bergman,et al.  Endoscopic management and follow-up of patients with a submucosal esophageal adenocarcinoma , 2018, United European gastroenterology journal.

[65]  A. Duhamel,et al.  Are Thoracotomy and/or Intrathoracic Anastomosis Still Predictors of Postoperative Mortality After Esophageal Cancer Surgery?: A Nationwide Study , 2017, Annals of surgery.

[66]  N. Demartines,et al.  Survival Benefit of Neoadjuvant Treatment in Clinical T3N0M0 Esophageal Cancer: Results From a Retrospective Multicenter European Study , 2017, Annals of surgery.

[67]  M. Pędziwiatr,et al.  Enhanced recovery after surgery protocol in oesophageal cancer surgery: Systematic review and meta-analysis , 2017, PloS one.

[68]  S. Kakar,et al.  HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and the American Society of Clinical Oncology. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[69]  K. Slim,et al.  Effect of prehabilitation in gastro-oesophageal adenocarcinoma: study protocol of a multicentric, randomised, control trial—the PREHAB study , 2016, BMJ Open.

[70]  C. Hassan,et al.  Esophageal stenting for benign and malignant disease: European Society of Gastrointestinal Endoscopy (ESGE) Clinical Guideline , 2016, Endoscopy.

[71]  Lixin Sun,et al.  Fast-track surgery improves postoperative clinical recovery and cellular and humoral immunity after esophagectomy for esophageal cancer , 2016, BMC Cancer.

[72]  S. Friesland,et al.  A randomized clinical trial of neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the oesophagus or gastro-oesophageal junction. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[73]  C. Strauss,et al.  Accuracy of staging laparoscopy in detecting peritoneal dissemination in patients with gastroesophageal adenocarcinoma. , 2016, Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus.

[74]  A. Duhamel,et al.  Role of neoadjuvant treatment in clinical T2N0M0 oesophageal cancer: results from a retrospective multi-center European study. , 2016, European journal of cancer.

[75]  K. Talsma,et al.  Impact of Neoadjuvant Chemoradiation on Lymph Node Status in Esophageal Cancer: Post hoc Analysis of a Randomized Controlled Trial. , 2015, Annals of surgery.

[76]  A. Duhamel,et al.  Laparoscopic Gastric Mobilization Reduces Postoperative Mortality After Esophageal Cancer Surgery: A French Nationwide Study. , 2015, Annals of surgery.

[77]  C. Mariette,et al.  Patterns of recurrence in early‐stage oesophageal cancer after chemoradiotherapy and surgery compared with surgery alone , 2015, The British journal of surgery.

[78]  Philippe Autier,et al.  Trends in colorectal cancer mortality in Europe: retrospective analysis of the WHO mortality database , 2015, BMJ : British Medical Journal.

[79]  T. Conroy,et al.  Early surgery for failure after chemoradiation in operable thoracic oesophageal cancer. Analysis of the non-randomised patients in FFCD 9102 phase III trial: Chemoradiation followed by surgery versus chemoradiation alone. , 2015, European journal of cancer.

[80]  A. Duhamel,et al.  Salvage Surgery After Chemoradiotherapy in the Management of Esophageal Cancer: Is It a Viable Therapeutic Option? , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[81]  L. Quéro,et al.  Salvage high-dose-rate brachytherapy for esophageal cancer in previously irradiated patients: A retrospective analysis. , 2015, Brachytherapy.

[82]  S. Mathoulin-Pélissier,et al.  Screening for Vulnerability in Older Cancer Patients: The ONCODAGE Prospective Multicenter Cohort Study , 2014, PloS one.

[83]  E. Steyerberg,et al.  Prolonged Time to Surgery After Neoadjuvant Chemoradiotherapy Increases Histopathological Response Without Affecting Survival in Patients With Esophageal or Junctional Cancer , 2014, Annals of surgery.

[84]  J. Bosset,et al.  Surgery alone versus chemoradiotherapy followed by surgery for stage I and II esophageal cancer: final analysis of randomized controlled phase III trial FFCD 9901. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[85]  C. Mariette,et al.  Does timing of surgical procedure after neoadjuvant chemoradiation affect outcomes in esophageal cancer? , 2014, The Annals of thoracic surgery.

[86]  T. Conroy,et al.  Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial. , 2014, The Lancet. Oncology.

[87]  C. Mariette,et al.  Is There a Role for Surgery for Patients with a Complete Clinical Response after Chemoradiation for Esophageal Cancer? An Intention-to-Treat Case-Control Study , 2013, Annals of surgery.

[88]  H. Matsubara,et al.  The Overall Prevalence of Metastasis in T1 Esophageal Squamous Cell Carcinoma: A Retrospective Analysis of 295 Patients , 2013, Annals of surgery.

[89]  D. Weishaupt,et al.  Accuracy of multidetector-row CT for restaging after neoadjuvant treatment in patients with oesophageal cancer , 2013, European Radiology.

[90]  N. Uedo,et al.  Long-Term Outcome and Metastatic Risk After Endoscopic Resection of Superficial Esophageal Squamous Cell Carcinoma , 2013, The American Journal of Gastroenterology.

[91]  C. Mariette,et al.  Percutaneous radiological gastrostomy in esophageal cancer patients: a feasible and safe access for nutritional support during multimodal therapy , 2013, Surgical Endoscopy.

[92]  R. Hicks,et al.  18F-FDG PET/CT Has a High Impact on Patient Management and Provides Powerful Prognostic Stratification in the Primary Staging of Esophageal Cancer: A Prospective Study with Mature Survival Data , 2012, The Journal of Nuclear Medicine.

[93]  E W Steyerberg,et al.  Preoperative chemoradiotherapy for esophageal or junctional cancer. , 2012, The New England journal of medicine.

[94]  Suzanne S Gisbertz,et al.  Minimally invasive versus open oesophagectomy for patients with oesophageal cancer: a multicentre, open-label, randomised controlled trial , 2012, The Lancet.

[95]  Paul Fockens,et al.  Standard endoscopy with random biopsies versus narrow band imaging targeted biopsies in Barrett's oesophagus: a prospective, international, randomised controlled trial , 2012, Gut.

[96]  P. Bossuyt,et al.  Accuracy and reproducibility of 3D-CT measurements for early response assessment of chemoradiotherapy in patients with oesophageal cancer. , 2011, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[97]  Hyae-Young Kim,et al.  Phase II study of weekly paclitaxel and capecitabine in patients with metastatic or recurrent esophageal squamous cell carcinoma , 2011, BMC Cancer.

[98]  V. Gebski,et al.  Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. , 2011, The Lancet. Oncology.

[99]  K. Geisinger,et al.  Outcomes of patients with esophageal cancer staged with [¹⁸F]fluorodeoxyglucose positron emission tomography (FDG-PET): can postchemoradiotherapy FDG-PET predict the utility of resection? , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[100]  Yoon-Koo Kang,et al.  Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial , 2010, The Lancet.

[101]  C. Klink,et al.  Operative outcome of colon interposition in the treatment of esophageal cancer: a 20-year experience. , 2010, Surgery.

[102]  A. Hölscher,et al.  [18F]-Fluorodeoxyglucose-Positron Emission Tomography for the Assessment of Histopathologic Response and Prognosis After Completion of Neoadjuvant Chemoradiation in Esophageal Cancer , 2009, Annals of surgery.

[103]  K. Slim,et al.  [Adoption in France of a surgical safety checklist]. , 2009, Journal de chirurgie.

[104]  K. Slim,et al.  [Digestive oncology: surgical practices]. , 2009, Journal de chirurgie.

[105]  N. Altorki,et al.  Predicting Systemic Disease in Patients With Esophageal Cancer After Esophagectomy: A Multinational Study on the Significance of the Number of Involved Lymph Nodes , 2008, Annals of surgery.

[106]  L. Gossner,et al.  Early Barrett's Carcinoma With “Low-Risk” Submucosal Invasion: Long-Term Results of Endoscopic Resection With a Curative Intent , 2008, The American Journal of Gastroenterology.

[107]  M. Mazumdar,et al.  Total Number of Resected Lymph Nodes Predicts Survival in Esophageal Cancer , 2008, Annals of surgery.

[108]  C. Mariette,et al.  The Number of Metastatic Lymph Nodes and the Ratio Between Metastatic and Examined Lymph Nodes Are Independent Prognostic Factors in Esophageal Cancer Regardless of Neoadjuvant Chemoradiation or Lymphadenectomy Extent , 2008, Annals of surgery.

[109]  P. Maingon,et al.  Phase III trial of protracted compared with split-course chemoradiation for esophageal carcinoma: Federation Francophone de Cancerologie Digestive 9102. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[110]  Wolfgang A Weber,et al.  PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial. , 2007, The Lancet. Oncology.

[111]  C. Mariette,et al.  Patients with Locally Advanced Esophageal Carcinoma Nonresponder to Radiochemotherapy: Who Will Benefit From Surgery? , 2007, Annals of Surgical Oncology.

[112]  T. Conroy,et al.  Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[113]  C. V. D. van de Velde,et al.  Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. , 2006, The New England journal of medicine.

[114]  C. Mariette,et al.  Should Resectable Esophageal Cancer Be Resected? , 2006, Annals of Surgical Oncology.

[115]  V. Gebski,et al.  Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial. , 2005, The Lancet. Oncology.

[116]  M. Feith,et al.  Biologic and clinical variations of adenocarcinoma at the esophago–gastric junction: Relevance of a topographic‐anatomic subclassification , 2005, Journal of surgical oncology.

[117]  Charles J. Lightdale,et al.  Update on the Paris Classification of Superficial Neoplastic Lesions in the Digestive Tract , 2005, Endoscopy.

[118]  Nils Lehmann,et al.  Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[119]  M. Ducreux,et al.  Combination of folinic acid, 5-fluorouracil bolus and infusion, and cisplatin (LV5FU2-P regimen) in patients with advanced gastric or gastroesophageal junction carcinoma. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[120]  T. Lipman,et al.  Percutaneous endoscopic gastrostomy before multimodality therapy in patients with esophageal cancer. , 2003, The Annals of thoracic surgery.

[121]  C. Mariette,et al.  Value of endoscopic ultrasonography as a predictor of long‐term survival in oesophageal carcinoma , 2003, The British journal of surgery.

[122]  R. Ginsberg,et al.  INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[123]  S. Griffin,et al.  Pattern of recurrence following radical oesophagectomy with two‐field lymphadenectomy , 2000, The British journal of surgery.

[124]  Y. Tachimori,et al.  Histopathologic findings predicting lymph node metastasis and prognosis of patients with superficial esophageal carcinoma , 2000, Cancer.

[125]  J. Cooper,et al.  Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. , 1999, JAMA.

[126]  H. Stein,et al.  Classification of adenocarcinoma of the oesophagogastric junction , 1998, The British journal of surgery.

[127]  J. Bosset,et al.  Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus. , 1997, The New England journal of medicine.

[128]  J. Cooper,et al.  Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. , 1992, The New England journal of medicine.

[129]  A. Wurtz,et al.  [Malpighian carcinoma of the thoracic esophagus: what x-ray computed tomographic classification?]. , 1988, Gastroenterologie clinique et biologique.

[130]  D. Nieboer,et al.  Individual risk calculator to predict lymph node metastases in patients with submucosal (T1b) esophageal adenocarcinoma: a multicenter cohort study , 2021, Endoscopy.

[131]  D. Groheux,et al.  [Update of the recommendations of good clinical practice for the use of PET in oncology]. , 2019, Bulletin du cancer.

[132]  M. Ducreux,et al.  Gastric cancer: French intergroup clinical practice guidelines for diagnosis, treatments and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO). , 2018, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[133]  H. Ishwaran,et al.  Cancer of the Esophagus and Esophagogastric Junction: An Eighth Edition Staging Primer , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[134]  K. Haustermans,et al.  Oesophageal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[135]  J. Bosset,et al.  Impact of neoadjuvant chemoradiation on lymph node status in esophageal cancer: post hoc analysis of a randomized controlled trial. , 2015, Annals of surgery.

[136]  MSc Edwin J. van Adrichem PT,et al.  Comparison of Two Preoperative Inspiratory Muscle Training Programs to Prevent Pulmonary Complications in Patients Undergoing Esophagectomy: A Randomized Controlled Pilot Study , 2014, Annals of Surgical Oncology.

[137]  T. Conroy,et al.  [Concurrent concentrated radio-chemotherapy of epidermoid cancer of the esophagus. Long-term results of a phase II national multicenter trial in 122 non-operable patients (FFCD 8803)]. , 2000, Gastroenterologie clinique et biologique.

[138]  T. Nishihira,et al.  A prospective randomized trial of extended cervical and superior mediastinal lymphadenectomy for carcinoma of the thoracic esophagus. , 1998, American journal of surgery.

[139]  Siewert,et al.  [Cardia cancer: attempt at a therapeutically relevant classification]. , 1987, Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen.